Pharvaris Shares Important Data on Bradykinin Receptor Antagonists
During the recent Bradykinin Symposium, Pharvaris (Nasdaq: PHVS) presented a compelling overview of data centered on its groundbreaking oral bradykinin B2 receptor antagonists. These treatments are designed to effectively prevent and manage hereditary angioedema (HAE) attacks. The presentations underscored the notable progress being made in therapeutic strategies for addressing this condition.
Emphasizing Long-Term Efficacy of Deucrictibant
One of the key presentations was titled Long-Term Safety and Efficacy of Oral Deucrictibant for HAE Prophylaxis, presented by Marc A. Riedl, M.D., M.S. This analysis, drawn from the open-label extension of the CHAPTER-1 Phase 2 study, demonstrated that a daily dosage of 40 mg of deucrictibant was well-tolerated, with no new safety issues arising. The key findings included:
- Ongoing treatment with deucrictibant successfully maintained the reduction in early-onset attacks seen in the placebo-controlled trial, achieving a median attack rate of zero over the course of a year in the open-label phase.
- Participants experienced fewer than one attack treatment per year with on-demand medication, highlighting the effectiveness of deucrictibant as a preventive option.
A Thorough Perspective on Attack Management
The presentation titled Treatment of HAE Attacks with Oral Deucrictibant: RAPIDe-2 Extension Results, delivered by Emel Aygören-Pürsün, M.D., revealed that the immediate-release capsule was both safe and well-received across all tested doses. The findings revealed:
- A median time to symptom relief of just 1.1 hours, with 98.5% of participants experiencing relief within 12 hours.
- The median time for severity reduction was 2.6 hours, with 97.7% of patients achieving significant relief by the 12-hour mark.
- Notably, 85.8% of participants experienced complete resolution of their attacks within 24 hours after taking a single dose of the immediate-release capsule.
Enhancing Quality of Life for Patients
Markus Magerl, M.D., shared valuable insights during an oral presentation on Prophylactic Treatment with Deucrictibant Improves HAE Disease Control and HRQoL. The randomized trial indicated that 90% of participants on deucrictibant reported better disease control compared to those on placebo. This presentation highlighted findings such as:
- Patients demonstrated improved scores on the Angioedema Quality of Life Questionnaire (AE-QoL), particularly in areas related to functionality and emotional well-being.
- Levels of satisfaction regarding treatment effectiveness were significantly higher among the deucrictibant group compared to those receiving placebo.
Comparative Effectiveness Against Standard Treatments
Further discussions included a poster presentation on Deucrictibant vs. Standard of Care in HAE: Propensity Score-Matched Analysis by Marc A. Riedl, M.D., M.S. This important study found that deucrictibant provided quicker relief compared to traditional treatments, reinforcing its potential as a more effective therapy for managing HAE attacks.
Investigating Cardiovascular Safety
Nieves Crespo, Ph.D., also shared findings regarding the cardiovascular safety of deucrictibant. Research conducted in non-human primate models indicated no adverse effects on cardiac health after prolonged exposure to the drug, addressing concerns about heart safety during HAE treatments.
Promoting Future Research
The necessity for ongoing research was a recurring theme in several presentations, which showcased innovative models like the bradykinin challenge model in humanized transgenic rats and various biomarker assays. These cutting-edge approaches hold promise for improving our understanding and management of bradykinin-mediated disorders.
About Deucrictibant and Pharvaris
Deucrictibant is recognized as a powerful oral small-molecule bradykinin B2 receptor antagonist. By targeting bradykinin signaling, it aims to prevent HAE attacks and effectively manage symptoms when they arise. Pharvaris, a biopharmaceutical innovator, is actively working on advanced formulations of deucrictibant to optimize both preventive and on-demand therapies for HAE. Currently, they are enrolling participants for pivotal Phase 3 studies aimed at further validating the efficacy of deucrictibant in real-world settings. Pharvaris remains committed to improving the quality of life for individuals affected by bradykinin-mediated angioedema.
Frequently Asked Questions
What is Pharvaris focused on developing?
Pharvaris specializes in creating innovative oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE).
What findings were presented about deucrictibant's safety?
The data indicated that deucrictibant was well-tolerated with no new safety signals, demonstrating its long-term safety in patients.
How does deucrictibant impact quality of life?
Patients reported improvements in quality of life measures, particularly in functional and emotional aspects when treated with deucrictibant.
What is the significance of the cardiovascular safety studies?
The studies showed no adverse effects on cardiac health after extended use of deucrictibant, supporting its safety profile.
What future studies is Pharvaris conducting?
Pharvaris is currently enrolling participants in pivotal Phase 3 studies to further evaluate the efficacy of deucrictibant for both preventive and acute treatment of HAE.
